Literature DB >> 19093165

Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.

Monika Ribeiro de Mello Conchon1,2,3, Israel Bendit4, Patricia Ferreira5, Walter Lima4, Cristina Kumeda5, Lucia Dias4, Dalton de Alencar Fischer Chamone4, Pedro Enrique Dorlhiac-Llacer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19093165     DOI： 10.1007/s12185-008-0224-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  13 in total

1.  Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

Authors:  M K Andersen; J Pedersen-Bjergaard; L Kjeldsen; I H Dufva; K Brøndum-Nielsen
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

2.  Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.

Authors:  Y L Chee; M A Vickers; D Stevenson; T L Holyoake; D J Culligan
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

3.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

Authors:  Thomas Bumm; Christel Müller; Haifa-Kathrin Al-Ali; Knut Krohn; Patricia Shepherd; Erika Schmidt; Sabine Leiblein; Christina Franke; Evelin Hennig; Thomas Friedrich; Reiner Krahl; Dietger Niederwieser; Michael W N Deininger
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

Review 4.  Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.

Authors:  Craig Kovitz; Hagop Kantarjian; Guillermo Garcia-Manero; Lynne V Abruzzo; Jorge Cortes
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

5.  Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

Authors:  M E O'Dwyer; K M Gatter; M Loriaux; B J Druker; S B Olson; R E Magenis; H Lawce; M J Mauro; R T Maziarz; R M Braziel
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

6.  Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

Authors:  C Terre; V Eclache; P Rousselot; M Imbert; C Charrin; C Gervais; M J Mozziconacci; O Maarek; H Mossafa; N Auger; N Dastugue; P Talmant; J Van den Akker; C Leonard; F N'Guyen Khac; F Mugneret; F Viguié; M Lafage-Pochitaloff; J N Bastie; G L Roux; F Nicolini; F Maloisel; N Vey; G Laurent; C Recher; M Vigier; Y Yacouben; S Giraudier; J P Vernant; B Salles; J Roussi; S Castaigne; V Leymarie; G Flandrin; M Lessard
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

7.  Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

Authors:  D M Ross; S Branford; S Moore; T P Hughes
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

8.  Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.

Authors:  José-Tomás Navarro; Evarist Feliu; Javier Grau; Blanca Espinet; Dolors Colomer; Josep-Maria Ribera; Albert Oriol; Isabel Granada; Jordi Juncà; Fuensanta Millá
Journal:  Am J Hematol       Date:  2007-09       Impact factor: 10.047

9.  Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Authors:  Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Mary Beth Rios; Kimberly Hayes; Jorge Cortes
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

10.  Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability.

Authors:  Alice Fabarius; Michelle Giehl; Oliver Frank; Birgit Spiess; Chun Zheng; Martin C Müller; Christel Weiss; Peter Duesberg; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998
View more
  1 in total

1.  [Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].

Authors:  J Wang; Yanli Zhang; J Zhou; Y L Zu; Z Li; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-05-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.